Introduction {#s1}
============

Many common structural birth defects appear to arise from a complex and ill-defined combination of genetic and environmental factors ([@bib49]). The notion that environmental agents affect penetrance and expressivity of predisposing mutations is speculated to underlie many human congenital anomalies, but has been difficult to demonstrate. Animal models are therefore valuable, but these have been slow to emerge. Some recent successful examples are a zebrafish model of craniofacial defects (*Pdgfra* mutations and fetal alcohol), and mouse models of scoliosis (Notch pathway mutations plus hypoxia), facial clefting (*Pax3* mutations plus 2,3,7,8-tetrachlorodibenzodioxin (TCDD)), and holoprosencephaly (Hedgehog pathway mutations and fetal alcohol) ([@bib33]; [@bib45]; [@bib65]; [@bib93]; [@bib103]).

Holoprosencephaly (HPE) is a common developmental defect in midline patterning of the forebrain and/or midface ([@bib69]). HPE occurs approximately once per 250 human conceptions, with an associated in utero lethality of \~97% ([@bib53]; [@bib89]). HPE is characterized by an unbroken continuum of rostroventral midline anomalies that range from complete failure to partition the forebrain into hemispheres plus cyclopia, through progressively less severe defects including partially partitioned forebrain, single nostril, and midface hypoplasia ([@bib18]; [@bib48]; [@bib69]).

Development of the rostroventral midline is initiated by signals derived from the prechordal plate (PCP) ([@bib44]; [@bib60]). The PCP produces Sonic hedgehog (SHH), initiating a sequence of events that progressively patterns the forebrain and midface ([@bib7]; [@bib22]; [@bib30]; [@bib44]; [@bib85]; [@bib105]). HH ligands trigger signaling by binding the primary receptor Patched1 (PTCH1). In the absence of ligand, PTCH1 constrains the activity of a second membrane protein, Smoothened (SMO). HH binding inhibits PTCH1 function, allowing SMO-dependent signals to activate GLI transcription factors and pathway-specific gene expression. HH ligand availability and signal reception are also regulated by a series of co-receptors and additional HH-binding proteins, including CDON, BOC, GAS1, and LRP2 ([@bib11]; [@bib47]; [@bib52]; [@bib77]; [@bib102]).

The PCP develops from the anterior primitive streak (APS) under the influence of Nodal pathway signaling ([@bib82]; [@bib87]; [@bib88]). Therefore, the Nodal pathway is developmentally upstream of the HH pathway in rostroventral midline patterning. Consistent with this conclusion, defective Nodal signaling at the primitive streak stage of development leads to defects in HH signaling and HPE ([@bib48]). Nodal is a TGFβ superfamily member and signals through a receptor complex including the type I and type II receptors, ALK4 and Activin receptor IIA/B (ActRIIA/B), and a GPI-linked co-receptor, TDGF1 (also called Cripto) ([@bib82]; [@bib87]; [@bib88]). Receptor activation results in phosphorylation of the transcription factors SMAD2 and SMAD3, and activation of genes required for PCP induction ([@bib82]; [@bib87]; [@bib88]). Among these genes are *Foxa2* and *Gsc* ([@bib5]; [@bib12]; [@bib29]). Nodal signaling also induces expression of *Lefty1* and *Lefty2*, which encode secreted inhibitors of the pathway that bind to TDGF1 and Nodal itself ([@bib82]; [@bib87]; [@bib88]).

The etiology of HPE is complex, involving both genetic and environmental risk factors ([@bib2]; [@bib27]; [@bib36]; [@bib40]; [@bib48]; [@bib73]; [@bib69]; [@bib74]; [@bib84]; [@bib96]). Heterozygous, loss-of-function mutations in components or regulators of the HH, Nodal, and FGF signaling pathways are associated with HPE ([@bib74]; [@bib84]). Epidemiology of HPE is less advanced than genetic analyses, but among the environmental risk factors implicated is fetal alcohol exposure ([@bib1]; [@bib19]; [@bib23]), though this is not always observed ([@bib2]). A full range of clinical phenotypes is seen in both sporadic and familial HPE ([@bib69]; [@bib90]). Many mutation carriers in pedigrees lack clinical manifestation, and many apparently sporadic cases have inherited a mutation from a minimally affected parent ([@bib51]; [@bib91]). It is likely, therefore, that HPE-associated mutations are not sufficient to produce midline defects, but are the substrate on which a complex landscape of genetic and/or environmental modifiers act. Statistical analysis is consistent with a multifactorial, 'autosomal dominant with modifier' model, wherein the penetrance and expressivity of a heterozygous driver mutation is graded by the modifier landscape ([@bib27]; [@bib36]; [@bib83]).

We have modeled this phenomenon in mice with high fidelity. *CDON* encodes a multi-functional co-receptor, including for the HH pathway, ([@bib58]; [@bib86]). *CDON* loss-of-function mutations have been identified in human HPE patients ([@bib9]; [@bib74]), but such variants are relatively common in the human population. Additionally, a patient with a rare homozygous *CDON* mutation displayed retinal coloboma, a mild HPE-associated eye phenotype also seen in *Cdon^-/-^* mice ([@bib13]; [@bib78]; [@bib106]). Therefore, *CDON* mutations likely require additional insults to contribute to HPE. Studies with mice are consistent with this conclusion. *Cdon^-/-^* mice on a 129S6 genetic background have a subthreshold defect in HH signaling and are subject to HPE induced by genetic and environmental modifiers; among the latter is ethanol (EtOH) ([@bib36]). *Cdon* mutation or in utero EtOH exposure individually yielded little effect on 129S6 mice. The combination, however, synergized to inhibit HH signaling in the developing forebrain and produced a complete spectrum of HPE phenotypes with high penetrance ([@bib33]). Furthermore, fetal EtOH induced a low penetrance of HPE in C57BL/6J mice, and this was exacerbated by heterozygosity for *Shh* or *Gli2* ([@bib45]). Consistent with the notion that a threshold of HH signaling activity is rate-limiting in midline patterning, genetic removal of one copy of the negative pathway regulator, *Ptch1*, rescued 129S6 *Cdon^-/-^* mice from EtOH-induced HPE ([@bib34]).

Defective HH pathway function may be a final common mechanism for all classical forms of HPE, so these results do not prove that HH signaling is the direct synergistic target of *Cdon* mutation and in utero EtOH exposure. Several lines of evidence argue that EtOH itself, rather than a consequence of its metabolism, is the HPE-inducing teratogen ([@bib35]). In this study, we demonstrate that the window of sensitivity to EtOH-induced HPE in 129S6 *Cdon^-/-^* mice is closed by embryonic day (E) 7.5, with the sensitivity period overlapping Nodal-mediated specification of the PCP from the APS. Furthermore, we find that CDON interacts genetically and physically with regulators of Nodal signaling. Finally, EtOH inhibits Activin/Nodal pathway signaling in vitro in mouse epiblast stem cells (mEpiSCs), which have transcriptional and functional properties that resemble APS cells ([@bib46]; [@bib98]). Together these results argue that, unexpectedly, *Cdon* mutation and fetal alcohol synergize to induce HPE by interfering with Nodal signaling. These results illuminate mechanisms of gene-environment interaction in a high fidelity, multifactorial model of a common birth defect.

Results {#s2}
=======

The window of sensitivity to EtOH-induced HPE coincides with Nodal signaling {#s2-1}
----------------------------------------------------------------------------

All studies were performed with mice on a 129S6 background and are referred to only by genotype unless otherwise noted. Our model uses one-hour timed mating of *Cdon^+/-^* mice, allowing rigorous identification of a window of sensitivity for EtOH's teratogenic effects. The standard EtOH treatment regimen involves one dose at E7.0 and a second dose four hours later. This results in a full range of HPE phenotypes in *Cdon^-/-^* mice with overall penetrance of \~75% ([@bib33]). The protocol is analogous to the original regimen developed to model fetal alcohol spectrum disorders in C57BL/6J mice, wherein \~ 19% developed HPE phenotypes ([@bib6]; [@bib95]). HPE phenotypes were not induced in wild type C57BL/6J mice when EtOH was administered at E6.5 or E7.5 ([@bib6]). We have shown that EtOH is ineffective in *Cdon^-/-^* mice when administered at E8.0 ([@bib33]). To further refine the temporal window of sensitivity, we assessed the ability of EtOH to induce HPE in *Cdon^-/-^* animals when administered at E7.25 and E7.5, with embryos examined for external HPE phenotypes at E14.0. EtOH was effective at E7.25, but not at E7.5 ([Table 1](#table1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

![Time course of EtOH-Induced HPE in *Cdon^-/-^* Embryos.\
Frontal views of E14.0 embryos. Treatment of *Cdon^-/-^* embryos with EtOH at E7.25, but not E7.5, results in HPE (see [Table 1](#table1){ref-type="table"} for quantification). The *Cdon^-/-^*embryo treated with EtOH at E7.25 displays a fused upper lip and single nostril (black arrow), whereas the *Cdon^-/-^*embryo treated with EtOH at E7.5 does not and resembles the saline control (red arrow).](elife-60351-fig1){#fig1}

###### Time course of EtOH-Induced HPE in *Cdon^-/-^* Embryos

  EtOH treatment:   E7.25         E7.5                                                    
  ----------------- ------------- ------------- ------------- ------------- ------------- -------------
  Phenotype\*       *Cdon^+/-^*   *Cdon^-/-^*   *Cdon^+/-^*   *Cdon^-/-^*   *Cdon^+/-^*   *Cdon^-/-^*
  Fused upper lip   0/17          2/14          0/21          13/24\*\*     0/13          0/22
  Single nostril    0/17          0/14          0/21          5/24          0/13          0/22
  Proboscis         0/17          0/14          0/21          2/24          0/13          0/22

\* All embryos with HPE had fused upper lip, a fraction of these showed single nostril and proboscis.

\*\*p=0.0165 by Fisher's two-tailed exact test, when compared to EtOH-treated *Cdon^+/-^* embryos.

EtOH itself is the HPE-inducing teratogen in this system ([@bib35]). The developmental processes directly perturbed by EtOH must therefore occur: 1) during the sensitive time window; and 2) prior to EtOH clearance, even if defects in midline development occur later. When administered at E7.0, maternal blood EtOH levels peaked at E7.25 and were no longer detectable by \~E7.75 ([@bib33]). Critically, EtOH is no longer effective at E7.5, a time reported to be prior to SHH expression and function in prechordal plate-mediated rostroventral midline patterning ([@bib28]; [@bib67]). These results argue that EtOH targets processes other than, or in addition to, HH signaling in *Cdon^-/-^* mice. Consistent with this conclusion, the time of peak sensitivity to HPE induced by the direct SMO inhibitor, Vismodegib, was E7.5, 6--12 hr later than for EtOH ([@bib32]).

Both the window of sensitivity to EtOH and peak EtOH levels overlap with induction of the PCP by Nodal signaling. We previously observed that expression of *Foxa2* and *Gsc*, two Nodal target genes that mark the APS (from which the PCP is derived), was diminished at E7.25 in EtOH-treated *Cdon^-/-^* embryos ([@bib33]). Both *Cdon* mutation and EtOH exposure were required for this effect. Expression of *Lefty2*, a direct Nodal pathway target gene, was also reduced at E7.25 specifically in EtOH-treated *Cdon^-/-^* embryos ([Figure 2](#fig2){ref-type="fig"}). Taken together, these results showed that the synergy between *Cdon* mutation and in utero EtOH exposure occurred during Nodal-dependent specification of the PCP and that reduction of Nodal target gene expression required a combination of mutation and teratogen. The observation that loss of CDON was required for the effect suggests that, in addition to its role as a SHH co-receptor, CDON functions earlier in development to promote midline patterning, potentially via the Nodal pathway. In fact, *Cdon* expression initiates during gastrulation and is seen in embryonic mesoderm and ectoderm ([@bib33]; [@bib70]).

![Defective Expression of *Lefty2* at the Primitive Streak Stage of EtOH-Treated *Cdon^-/-^* Embryos.\
Whole mount in situ hybridization analyses of *Lefty2* in embryos of the indicated genotype and treatment harvested at E7.25. *Lefty2* expression was decreased specifically in EtOH-treated *Cdon^-/-^* embryos. Numbers of embryos with similar results: *Cdon^+/-^* (saline) = 6; *Cdon^+/-^* (EtOH) = 4; *Cdon^-/-^* (saline) = 9; *Cdon^-/-^* (EtOH) = 9. Scale Bar, 200 μm.](elife-60351-fig2){#fig2}

*Cdon* interacts genetically with Nodal pathway components {#s2-2}
----------------------------------------------------------

Mice with mutations resulting in complete loss of Nodal signaling gastrulate abnormally and die early in development, but hypomorphic pathway mutants display a range of HPE phenotypes ([@bib4]; [@bib17]; [@bib57]; [@bib75]; [@bib87]; [@bib88]; [@bib92]). To further probe the linkage between CDON and regulation of Nodal signaling, we assessed whether *Cdon* interacted genetically with *Tdgf1* and *Lefty2*, direct positive and negative regulators of the Nodal pathway, respectively. When analyzed at E10,\~14% of *Cdon^-/-^* embryos treated with EtOH had alobar HPE and cyclopia, dying in utero by E11 ([@bib33]; [@bib34]). When studied at E14,\~70% of such embryos displayed lobar HPE and a range of craniofacial midline phenotypes, including fused upper lip and single nostril ([@bib33]; [@bib34]). To address genetic interactions between *Cdon* and Nodal pathway regulators, we took advantage of the high penetrance of phenotypes at E14 and analyzed embryos at this stage for these unambiguous, easily scored phenotypes.

Targeted mutations in *Tdgf1* and *Lefty2* ([@bib25]; [@bib68]) were placed onto the 129S6 genetic background and then crossed to *Cdon* mutants to generate double heterozygotes. Offspring of intercrosses of these mice were further crossed and pregnant females were treated with EtOH or saline as a control. *Tdgf1* is essential for Nodal signaling. *Lefty2* is induced in response to Nodal signaling to provide critical negative feedback as an inhibitor of the pathway. Since CDON and EtOH may act together at the level of Nodal signaling in HPE, we predicted that removal of one copy of *Tdgf1* would sensitize *Cdon^-/-^* embryos to EtOH-induced HPE. In contrast, removal of one copy of *Lefty2* would be predicted to rescue *Cdon^-/-^* embryos from EtOH-induced HPE. (Null mutations in *Tdgf1* and *Lefty2* result in early lethality due to strong gastrulation defects ([@bib25]; [@bib68]), so studying homozygous double mutants with *Cdon* is impossible.) To permit the detection of sensitization by *Tdgf1* heterozygosity, we used a dose of EtOH which we previously reported gives \~30% penetrance of HPE at E14 (2.9 g/kg) ([@bib33]). With this regimen, 28% of EtOH-treated *Cdon^-/-^;Tdgf1^+/+^* embryos had HPE, whereas 55% of *Cdon^-/-^;Tdgf1^+/-^* embryos did (p\<0.014) ([Table 2](#table2){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}). With the exception of a single EtOH-treated *Cdon^+/-^;Tdgf1^+/-^* embryo, EtOH-treated mice of other genotypes and saline-treated control mice did not display HPE. Removal of one copy of *Tdgf1* therefore sensitized *Cdon^-/-^* mice to EtOH-induced HPE.

![*Tdgf1* Heterozygosity Enhances EtOH-Induced HPE in *Cdon^-/-^* Embryos.\
Frontal views of E14.0 embryos. Removal of one copy of *Tdgf1* enhanced the response of *Cdon^-/-^* embryos to a dose of 2.9 g/kg EtOH (see [Table 2](#table2){ref-type="table"} for quantification). The EtOH-treated *Cdon^-/-^;Tdgf1^+/-^* embryo displays a fused upper lip (arrow).](elife-60351-fig3){#fig3}

###### *Tdgf1* Heterozygosity Enhances EtOH-Induced HPE in *Cdon^-/-^* Embryos.

  Treatment         Genotype (\# embryos with HPE/total (%))\*                            
  ----------------- -------------------------------------------- ------------------------ ------------------------
                    *Cdon^+/-^;Tdgf1^+/-^*                       *Cdon^-/-^;Tdgf1^+/+^*   *Cdon^-/-^;Tdgf1^+/-^*
  Saline            0/23 (0%)                                    0/11 (0%)                2/27 (7.4%)
  EtOH (2.9 g/kg)   1/48 (2.1%)                                  9/32 (28.1%)             31/56 (55.4%)\*\*

\* Crosses between the following genotypes were used to generate the genotypes scored above:.

*Cdon^+/-^;Tdgf1^+/-^* x *Cdon^+/-^;Tdgf1^+/-^*.

*Cdon^+/-^;Tdgf1^+/-^* x *Cdo-^+/-^;Tdgf1^+/-^*.

*Cdon^+/-^* x *Cdon^+/-^;Tdgf1^+/-^*.

*Cdon^+/-^* x *Cdon^-/-^;Tdgf1^+/-^*.

*Cdon^-/-^* x *Cdon^+/-^;Tdgf1^+/-^*.

No HPE was found in offspring genotypes other than those shown.

\*\* p=0.014 by Fisher\'s two-tailed exact test, when compared to EtOH-treated *Cdon^-/-^; Tdgf1* ^+/+^ embryos.

*Nodal^-/-^* and *Lefty2^-/-^* embryos have opposite defects in gastrulation and display dosage-dependent genetic interactions, with *Lefty2* functioning as a negative regulator of the pathway ([@bib68]). To test for phenotypic suppression in EtOH-induced HPE, we used the standard dose of EtOH (3.48 g/kg) for these analyses, as it results in high penetrance. All embryos with HPE at E14 display a fused upper lip, while only some show the more severe single nostril phenotype. Approximately 70% of EtOH-treated *Cdon^-/-^;Lefty2^+/+^* embryos had a fused upper lip, similar to our previous findings ([@bib33]; [@bib34]), whereas 54% of *Cdon^-/-^;Lefty2^+/-^* embryos did, revealing a trend toward overall reduction of HPE frequency (p=0.14). However, while 21% of EtOH-treated *Cdon^-/-^;Lefty2^+/+^* embryos had a single nostril, only 6% of *Cdon^-/-^;Lefty2^+/-^* embryos did (p=0.04) ([Table 3](#table3){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"} ). Again, EtOH-treated mice of other genotypes and saline-treated control mice did not display HPE. Therefore, removal of one copy of *Lefty2* rescued a more severe form of HPE associated with EtOH treatment. Taken together, these studies revealed that the Nodal signaling components *Tdgf1* and *Lefty2* act as heterozygous enhancer and suppressor genes, respectively, of EtOH-induced HPE in *Cdon^-/-^* embryos.

![*Lefty2* Heterozygosity Suppresses EtOH-Induced HPE in *Cdon^-/-^* Embryos.\
Frontal views of E14.0 embryos. Removal of one copy of *Lefty2* suppressed formation of single nostril in *Cdon^-/-^* embryos in response to a dose of 3.48 g/kg EtOH (see [Table 3](#table3){ref-type="table"} for quantification). The EtOH-treated *Cdon^-/-^* embryo displays a fused upper lip and single nostril (black arrow), whereas the EtOH-treated *Cdon^-/-^;Lefty2^+/-^* embryo has a fused upper lip and two nostrils (red arrow).](elife-60351-fig4){#fig4}

###### *Lefty2* Heterozygosity Supresses EtOH-Induced HPE in *Cdon^-/-^* Embryos.

  Treatment          Genotype (\# affected/total (%))\*                                                       
  ------------------ ------------------------------------ ------------------------- ------------------------- -------------------------
                     Total HPE                            Single nostril                                      
                     *Cdon^-/-^;Lefty2^+/+^*              *Cdon^-/-^;Lefty2^+/-^*   *Cdon^-/-^;Lefty2^+/+^*   *Cdon^-/-^;Lefty2^+/-^*
  Saline             1/12 (8.3%)                          0/10 (0%)                 0/12 (0%)                 0/10 (0%)
  EtOH (3.48 g/kg)   33/47 (70.2%)                        26/48 (54.2%)             10/47 (21.3%)             3/48 (6.3%)\*\*

\* Crosses between the following genotypes were used to generate the genotypes scored above:.

*Cdon^+/-^;Lefty2^+/-^* x *Cdon^+/-^;Lefty2^+/-^*.

*Cdon^+/-^;Lefty2^+/-^* x *Cdo-^+/-^;Lefty2^+/-^*.

*Cdon^+/-^* x *Cdon^+/-^;Lefty2^+/-^*.

*Cdon^+/-^* x *Cdo^-/-^;Lefty2^+/-^*.

*Cdon^-/-^* x *Cdon^+/-^;Lefty2^+/-^*.

No HPE was found in offspring genotypes other than those shown.

\*\*p=0.04 by Fisher\'s two-tailed exact test, when compared to EtOH-treated *Cdon^-/-^;Lefty2^+/+^* embryos with a single nostril.

EtOH inhibits Activin/Nodal signaling in mEpiSCs {#s2-3}
------------------------------------------------

The APS is a small, transiently existing cell population, making it hard to study directly. Cultured mEpiSCs have transcriptional and functional properties resembling APS cells ([@bib46]; [@bib98]), making them a tractable in vitro surrogate model. mEpiSCs rely on FGF2 and Activin/Nodal signaling for maintenance as self-renewing, pluripotent stem cells ([@bib14]; [@bib99]). Activin A and Nodal use the same receptor and signaling mechanism, except that Nodal, but not Activin A, requires the co-receptor TDGF1. Therefore, we evaluated the effects of EtOH on Activin/Nodal signaling in mEpiSCs.

A direct readout of Nodal signaling activity is receptor-mediated phosphorylation of SMAD2 at its C-terminus ([@bib82]; [@bib87]; [@bib88]). We assessed C-terminally phosphorylated SMAD2 (p-SMAD2C) and total SMAD2 levels in the mEpiSC line, EpiSC9 ([@bib72]), after treatment with EtOH for 6 hr. A relatively short treatment duration was chosen because: 1) the in vivo model is an acute exposure regimen; 2) the window of sensitivity to EtOH-induced HPE is \<12 hr; and 3) high EtOH levels last only about 10 hr in pregnant females ([@bib33]). EtOH dose-dependently diminished p-SMAD2C levels in mEpiSCs, without altering total SMAD2 levels ([Figure 5A,B](#fig5){ref-type="fig"}).

![Acute EtOH treatment inhibits activin/nodal signaling in mEpiSCs.\
(**A**) Representative western blot of mEpiSCs treated with the indicated doses of EtOH for 6 hr. GAPDH was used as a loading control. (**B**) Densitometric quantification of p-SMAD2C levels, relative to total Smad2; p-JNK1 levels, relative to total JNK1; and p-SMAD2L levels, relative to total SMAD2, with the indicated doses of EtOH. N = 3 experiments with two biological replicates (as shown in (**A**)) in each experiment. (**C**) qRT-PCR analysis of *Nanog*, *Nodal*, *Pou5f1*, and *Sox2* expression in mEpiSCs treated with the indicated doses of EtOH for 6 hr. Expression was normalized to *Gapdh* expression. N = 3 experiments with two biological replicates in each experiment. Values for (**B**) and (**C**) are means ± SEM, \*p\<0.05, \*\*p\<0.01, \*\*\*p,0.001 by Student's t-test.\
Figure 5---source data 1.Source data for quantification of western blot results shown in [Figure 5A and B](#fig5){ref-type="fig"}.\
Figure 5---source data 2.Source data for quantification of qRT-PCR results shown in Figure 5C.](elife-60351-fig5){#fig5}

EtOH stimulates activation of the MAP kinase, JNK, in specific cell types ([@bib63]; [@bib80]). SMAD2 is phosphorylated in its linker region by MAP kinases ([@bib61]; [@bib81]), usually leading to inhibition of SMAD2 function ([@bib31]; [@bib50]; [@bib54]). We therefore assessed total and phosphorylated (activated) forms of JNK1 MAP kinase in EtOH-treated mEpiSCs. EtOH dose-dependently increased phospho-JNK1 (T183/Y185) levels (p-JNK1; [Figure 5A,B](#fig5){ref-type="fig"}). Consistent with EtOH-induced p-JNK1 activation, phosphorylation of the SMAD2 linker region (p-SMAD2L) also occurred in an EtOH dose-dependent manner, with production of p-JNK1 and p-SMAD2L correlating well ([Figure 5A,B](#fig5){ref-type="fig"}).

Human embryonic stem cells (hESCs) resemble mEpiSCs ([@bib76]). Treatment of hESC or mEpiSC cultures with the ALK4 inhibitor, SB43152, led to reduction of Activin/Nodal target gene expression and, eventually, induction of early markers of neuroectoderm differentiation ([@bib15]; [@bib55]; [@bib56]; [@bib99]). These studies generally used time courses of days to weeks, but Vallier et al. assessed expression of five Activin/Nodal target and/or pluripotency-related genes in hESCs treated with SB43152 for 6 hr, the same amount of time we treated mEpiSCs with EtOH. Levels of *Nanog*, *Nodal*, and *LeftyA* mRNA were reduced by SB43152, whereas levels of *Pou5f1* (also called *Oct4*) and *Sox2* underwent little or no change ([@bib99]). We assessed expression of these five genes in mEpiSCs treated with EtOH for 6 hr ([Figure 5C](#fig5){ref-type="fig"}). Similar to SB43152-treated hESCs, EtOH-treated mEpiSCs displayed significantly reduced levels of *Nanog* and *Nodal* mRNAs, while *Pou5f1* and *Sox2* mRNA levels were largely unchanged. Expression of the additional SB43152-inhibitable mEpiSC markers *Fgf5* and *T* ([@bib56]) were also reduced by EtOH treatment ([Figure 5C](#fig5){ref-type="fig"}). In contrast, EtOH did not alter levels of *Lefty1* or *Lefty2* in mEpiSC cultures ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). As these are known Activin/Nodal target genes, this result might be related to differences in SB43152 vs. EtOH treatment, or differences in half-lives of these mRNAs in human vs. mouse cultures. Therefore, acute EtOH treatment of mEpiSCs resulted in an inhibitory SMAD2 phosphorylation pattern and changes in gene expression similar to those induced by a direct Activin/Nodal pathway inhibitor. Induction of neuroectoderm-specific genes (e.g., *Hoxa1*, *Six1*, and *Gbx2*) was observed in hESCs treated with SB43152 for 2--6 days ([@bib15]; [@bib99]). After 6 hr of EtOH treatment, we found a varied response, with *Hoxa1* levels strongly induced, *Six1* expression displaying a biphasic dose-response, and *Gbx2* levels reduced ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

*Cdon* and *Lrp2* genetically interact in mice to generate phenotypes resembling Nodal pathway hypomorphs, and both bind to TDGF1 {#s2-4}
---------------------------------------------------------------------------------------------------------------------------------

Our findings argue that CDON plays an earlier role in development than its known function as a SHH co-receptor. The need for EtOH exposure to reveal this role suggests that CDON's effects in primitive streak embryos may be redundant with other factors. The HH co-receptors BOC and GAS1 are not likely to be such factors, as *Cdon;Boc;Gas1* triple knockout mice had a phenotype that is close to a complete loss of embryonic HH pathway function, but not Nodal pathway-like phenotypes ([@bib3]). LRP2 is an endocytic and auxiliary receptor for multiple morphogenetic ligands and receptors ([@bib102]). *Lrp2^-/-^* mice have HPE of variable penetrance and severity ([@bib16]; [@bib94]; [@bib102]; [@bib101]). We therefore constructed mice with mutations in *Cdon* and *Lrp2*. Some *Cdon;Lrp2* double mutants at E11.5 had a severe truncation of anterior head and face structures, a phenotype neither single mutant displayed ([Figure 6A](#fig6){ref-type="fig"}). Double-mutant embryos studied at several stages displayed a range of phenotypes, including milder craniofacial truncation and strong HPE ([Figure 6B,C](#fig6){ref-type="fig"}). Of 30 *Cdon;Lrp2* double mutants scored between 20 and 37 somites, 24 (80%) had HPE and 6 (20%) displayed anterior truncations. Loss of anterior head structure is a more severe phenotype than that seen even in *Smo* mutants, which lack all HH signaling ([@bib104]). These phenotypes -- anterior truncations and HPE -- are similar to those observed in mice with partial loss of Nodal pathway function (e.g., hypomorphic *Nodal* and *Tdgf1* mutants, and *Nodal^+/-^;Smad2^+/-^* mutants, each have phenotypes that include truncation of anterior head structures and severe HPE) ([@bib4]; [@bib17]; [@bib57]; [@bib75]; [@bib92]). The *Cdon*/*Lrp2* genetic interaction is specific and selective: the *Cdon* paralog *Boc* is not expressed in primitive streak-stage embryos ([@bib71]; [@bib104]), and *Boc* mutant mice do not synergize with *Lrp2* mutants (unpublished results), nor are they sensitive to EtOH-induced HPE ([@bib33]).

![*Cdon* and *Lrp2* Interact Genetically to Produce HPE and Anterior Truncations in Mice.\
(**A**) Whole mount E11.5 embryos of the indicated genotype. Note the loss of anterior head structures in the *Cdon^-/-^;Lrp2^-/-^* embryo (arrow). (**B**) E18.5 embryos of the indicated genotype in whole mount and alizarin red/alcian blue-stained skeleton preparations. Note the craniofacial truncation in the *Cdon^-/-^;Lrp2^-/-^* embryos (arrows). (**C**) Whole mount P0 *Cdon^-/-^;Lrp2^-/-^* embryo showing severe HPE.](elife-60351-fig6){#fig6}

CDON is a multifunctional co-receptor and promotes HH-independent signaling when associated with various other receptors and cell adhesion molecules. In addition to binding HH ligands and PTCH1, CDON interacts with and influences signaling by classical cadherins; the Netrin receptor, Neogenin; and the WNT co-receptor, LRP6 ([@bib9]; [@bib8]; [@bib38]; [@bib39]; [@bib42]; [@bib43]; [@bib58]; [@bib97]). We hypothesized that CDON might work similarly in Nodal signaling. To address this possibility, we assessed whether CDON binds to Nodal receptor components. A secreted CDON ectodomain fused in-frame at its carboxy terminus with the IgG Fc region (CDON-Fc) was expressed in HEK293T cells with individual ectodomains of the Nodal receptor (ActRIIA, ActRIIB, ALK4, and TDGF1) fused in-frame at their carboxy termini with alkaline phosphatase (AP). As positive and negative controls, SHH-N-AP and CD164-AP were used, respectively (SHH-N is the active portion of SHH, CD164 is a cell surface sialomucin) ([@bib41]; [@bib97]). The use of secreted ectodomains reduces the possibility that unknown, cell surface-bound factors promote binding or contribute directly to the complex. Conditioned medium was collected, and equivalent amounts of AP fusion proteins from conditioned media were pulled down and blotted for captured CDON-Fc. Conversely, equivalent levels of Fc were pulled down, and associated AP activity was quantified. Similar results were obtained in each pull-down: CDON-Fc interacted efficiently with TDGF1-AP, similar to the interaction between CDON-Fc and SHH-N-AP ([Figure 7A,B](#fig7){ref-type="fig"}). CDON-Fc did not bind to the negative control CD164-AP, and it interacted only weakly with the AP-tagged versions of ALK4, ActRIIA, and ActRIIB ([Figure 7A,B](#fig7){ref-type="fig"}).

![CDON and LRP2 Bind to TDGF1.\
(**A**) The indicated AP-tagged proteins were co-expressed with CDON-Fc, and equivalent amounts of AP proteins in conditioned medium (CM) were pulled down. Levels of CDON-Fc in CM and in the pull down were detected by western blot. (**B**) CDON-Fc was pulled down from CM derived from transfections as in (**A**), the amount of CDON-Fc from various CM normalized, and associated AP enzyme activity quantified, N = ≥4 for (**A**) and (**B**). (**C**) Schematic of full length LRP2 and recombinant mini-receptor variants used. Each mini-receptor spans one of the four repetitive modules of the extracellular receptor domain and was expressed either as soluble ectodomain fragments fused to IgG Fc (designated sR1- sR4) or as a membrane-bound mini-receptor fused to the authentic transmembrane and intracellular domains of LRP2 (designated R1- R4). Soluble ectodomain fragments sR1 -- sR4 were studied in panel (**D**), whereas mini-receptors R1 -- R4 were used in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"} . Amino acid numbers next to the full-length receptor polypeptide indicate the extent of individual receptor domains. (**D**) The indicated Fc-tagged proteins were pulled down from CM derived from transfections as in (**A**), the amount of Fc-tagged protein from various CM normalized, and associated AP enzyme activity quantified, N = 3. Values for (**B**) and (**D**) are means ± SEM, \*p\<0.05, \*\*p\<0.01 by Student's t-test.\
Figure 7---source data 1.Source data for quantification of AP activity in CDON-Fc pulldown experiments shown in [Figure 7B](#fig7){ref-type="fig"}.\
Figure 7---source data 2.Source data for quantification of AP activity in CDON-Fc and soluble LRP2 minireceptor-Fc pulldown experiments shown in [Figure 7D](#fig7){ref-type="fig"}.](elife-60351-fig7){#fig7}

As CDON and LRP2 interacted genetically to produce Nodal hypomorph-like phenotypes, we asked whether LRP2, like CDON, binds to TDGF1. The extracellular region of LRP2 harbors four repetitive modules, each comprising a cluster of complement-type repeats followed by EGF-type repeats and β-propellers. Each module is likely capable of independently binding ligands, as shown for the related receptor, LRP1 ([@bib24]). LRP2 is a huge polypeptide of 4660 amino acids, making it difficult to express in vitro. Therefore, we constructed a series of soluble 'mini-receptors' (designated sR1, sR2, sR3, and sR4) spanning virtually the entire ectodomain in four non-overlapping pieces, each fused in-frame at their carboxy termini to the IgG Fc region (see [Figure 7C](#fig7){ref-type="fig"}). Each soluble ectodomain segment and TDGF1-AP were expressed in HEK293T cells and assessed for their ability to bind to each other. LRP2 binds SHH-N ([@bib16]; [@bib64]), so this ligand was used again as a positive control, with CD164-AP serving as a presumptive negative control. Each soluble LRP2 mini-receptor ectodomain (i.e., sR1 to sR4) pulled down SHH-N-AP, revealing that LRP2 harbors multiple SHH-N binding sites ([Figure 7D](#fig7){ref-type="fig"}). These results were confirmed by expressing each ectodomain segment joined with the native LRP2 transmembrane and cytoplasmic domains (mini-receptors R1, R2, R3, and R4; [Figure 7C](#fig7){ref-type="fig"}) in NIH3T3 cells. These cultures were incubated with recombinant SHH-N-GST fusion proteins for 2 hr, followed by immunoprecipitation with anti-LRP2 antibody recognizing all mini-receptors and western blotting with antibodies to LRP2 or GST. Again, all four mini-receptors pulled down SHH-N, whereas no pulldown of SHH-N was seen in control transfectants lacking LRP2 mini-receptors ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Finally, we assessed LRP2 binding to TDGF1 with the soluble ectodomain binding assay. Similar to its multivalent interaction with SHH-N, the soluble LRP2 ectodomain segments sR3 and sR4 pulled down TDGF1-AP ([Figure 7D](#fig7){ref-type="fig"}). Soluble LRP2 ectodomain segments sR1 and sR2 also pulled down TDGF1-AP, but greater variability in the interaction was observed, leading to p\>0.05 (p=0.14 and p=0.06, respectively). The efficiency of LRP2 mini-receptor ectodomains to bind SHH-N-AP and TDGF1-AP was similar to that of CDON-Fc ([Figure 7D](#fig7){ref-type="fig"}).

Discussion {#s3}
==========

HPE is a common developmental disorder, but its etiology remains poorly understood. Mutations in the Nodal, HH, and FGF pathways are associated with HPE ([@bib74]), but these alone are insufficient to drive aberrant development. Identifying and understanding the critical phenotypic modifiers of such mutations is important but still in its infancy. Many birth defects are thought to be caused by poorly defined interactions between genetic and environmental risk factors, but the mechanistic bases of these interactions are largely unknown ([@bib49]). *Cdon* mutation and fetal alcohol are each implicated in human HPE ([@bib1]; [@bib9]; [@bib19]; [@bib23]; [@bib74]), though neither may be sufficient. The *Cdon* mutation plus fetal alcohol model is noteworthy for its specificity and fidelity to many aspects of human HPE ([@bib33]). Therefore, illumination of how loss of *Cdon* interacts with in utero EtOH exposure provides insight into mechanisms of HPE and how fetal alcohol functions as a teratogen.

The Nodal pathway is developmentally upstream from the HH pathway in patterning the rostroventral midline. While CDON is clearly a component of the HH pathway, it regulates signaling within several additional pathways as well ([@bib9]; [@bib8]; [@bib38]; [@bib39]; [@bib42]; [@bib43]; [@bib58]; [@bib97]). Multiple lines of evidence presented here argue that CDON also regulates Nodal signaling and that the Nodal pathway is a major point of synergistic interaction between mutation of *Cdon* and fetal EtOH exposure. The evidence includes: (1) EtOH-treated *Cdon^-/-^* embryos display defects in expression of Nodal target genes in the APS (including *Gsc*, *Foxa2*, and *Lefty2*), whereas EtOH treatment or *Cdon* mutation alone do not ([@bib33]; this study); (2) the window of sensitivity to EtOH-induced HPE is very narrow and closed by E7.5, a time reported to be prior to SHH expression and function in prechordal plate-mediated rostroventral midline patterning; (3) EtOH itself is the likely HPE-inducing teratogen and peak circulating EtOH levels coincide with Nodal signaling in the APS; (4) *Cdon* interacts genetically with the critical Nodal pathway factors *Tdgf1* and *Lefty2* in EtOH-induced HPE; (5) acute EtOH treatment dose-dependently diminishes p-SMAD2C and elevates p-SMAD2L levels, and inhibits Activin/Nodal-dependent gene expression, in mEpiSCs; (6) *Cdon;Lrp2* double mutants display phenotypes similar to mice with hypomorphic Nodal pathway mutations, including anterior truncations, a phenotype not seen in mice lacking all HH signaling; and (7) CDON and LRP2 both bind efficiently to TDGF1, an essential component of the Nodal receptor. We note that although EtOH inhibited p-SMAD2C production in mEpiSCs, and diminished expression of Nodal target genes in both mEpiSCs and *Cdon^-/-^* embryos, we have not yet demonstrated that EtOH inhibits p-SMAD2C production in embryos; additional work is therefore required to show the mechanisms in vitro and in vivo operate at the same level. Similarly, analysis of Nodal signaling in *Cdon;Lrp2* double mutant embryos requires study.

Together our findings are consistent with the following model: CDON and LRP2 function with overlapping or compensatory roles to regulate Nodal pathway signaling in the APS during induction of the PCP. Brief exposure of *Cdon^-/-^* embryos to EtOH during this period transiently and partially inhibits Nodal pathway activity. While all the mice successfully gastrulate, they emerge from this period predisposed towards development of HPE in a stochastic manner. If HH signaling strength fails to reach a required threshold early during rostroventral midline patterning, at the PCP stage, the outcome is alobar HPE and cyclopia; if it occurs at later stages of development, the outcomes are progressively less severe. Aspects of the model will require additional experimentation, but it is logically consistent with the synergistic effects of fetal alcohol and *Cdon* mutation within a narrow window of sensitivity, and also with the 'mutation plus modifier' view of human HPE. Our findings do not exclude that EtOH may also target HH signaling in *Cdon^-/-^* mice, but they are consistent with Nodal signaling being a major target of EtOH in HPE.

The specific mechanisms whereby acute EtOH treatment reduces expression of Nodal target genes in the APS of *Cdon^-/-^* mice and diminishes Activin/Nodal signaling in mEpiSCs are not known. EtOH itself, rather than consequences of its oxidative metabolism, is very likely the HPE-inducing teratogen ([@bib35]). An alternative mechanism to metabolism-based toxicity is that EtOH itself functions to perturb cell membranes via its hydrophobicity ([@bib59]; [@bib66]). One possibility is that EtOH's hydrophobic nature perturbs trafficking of Nodal receptor components or their stable assembly at the cell surface. TDGF1 is a GPI-linked protein, so might be especially vulnerable to hydrophobic membrane perturbation. However, exogenously provided Activin A is the major activator of SMAD2 in cultured mEpiSCs, and Activin does not require TDGF1 to signal through ActRII/ALK4. EtOH reduces p-SMAD2C levels in these cultures, so TDGF1 may not be a direct critical target of EtOH. Nevertheless, mEpiSCs endogenously express Nodal ([@bib46]), which does require TDGF1, and its contribution to SMAD2 signaling in these cultures is not fully clear. Additionally, EtOH activates JNK1 in mEpiSCs, with a corresponding increase in p-SMAD2L levels. Phosphorylation of SMAD2 by MAP kinases is generally inhibitory to SMAD2 activity, independent of p-SMAD2C phosphorylation status ([@bib61]; [@bib81]), so EtOH appears to promote or inhibit multiple signals that converge on SMAD2 phosphorylation.

CDON regulates several signaling pathways, but it has not previously been implicated in Nodal signaling. How CDON functions to regulate Nodal signaling is of obvious interest. *Cdon;Lrp2* double mutant mice display phenotypes that resemble Nodal pathway hypomorphs, and CDON and LRP2 each bind to TDGF1. Therefore, as with the effects of EtOH, TDGF1 is a possible point of regulation. One potential mechanism is that CDON and LRP2 might function as components of a larger Nodal receptor complex, contributing via interaction with TDGF1. Alternatively, they may work with TDGF1 in processing and trafficking of Nodal or other receptor components, or play a role in processing and trafficking of TDGF1 itself ([@bib21]). There is evidence in other systems that CDON and LRP2 can act in such a manner. LRP2 is best understood as an endocytic receptor that controls internalization and intracellular trafficking of both soluble and membrane-bound proteins, including PTCH1, the Na^+^/H^+^ exchanger NHE3, and the intrinsic factor receptor, Cubilin ([@bib102]). Furthermore, CDON regulates subcellular localization of N-cadherin during neural crest migration in zebrafish ([@bib79]). Similarly, the *Drosophila* orthologs of CDON act not only as co-receptors for HH, but in trafficking of the primary HH receptor, PTC ([@bib107]). Another possibility is in regulation of cell-cell contact and adhesion. CDON is localized to sites of cell-cell contact and functions with N-cadherin in cell adhesion-dependent signaling ([@bib42]; [@bib58]). In zebrafish, a positive feedback loop exists between Nodal signaling, E-cadherin expression, and duration of cell-cell contact, that directs PCP specification at the expense of endoderm specification ([@bib10]). It is conceivable that CDON could play a role in adhesion-mediated, higher order regulatory events like this as well. These varied potential mechanisms are not mutually exclusive.

Our findings offer insight into how *Cdon* mutation synergizes with fetal alcohol in mice to produce a wide spectrum of HPE phenotypes, closely resembling the complex etiology and variable outcomes seen in humans at the population level. A combination of approaches, including window of sensitivity studies, genetic interactions in mice, and in vitro analyses revealed that, unexpectedly, a major point of synergy is at the level of Nodal signaling. These findings illuminate gene-environment interactions in the causation of a common birth defect, expand understanding of alcohol teratogenesis, and serve as a conceptual framework for additional developmental anomalies.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\            Designation                                     Source or reference               Identifiers                   Additional\
  or resource                                                                                                                                        information
  ---------------------------------- ----------------------------------------------- --------------------------------- ----------------------------- -------------------------
  Genetic reagent (*Mus musculus*)   Cdon^-^                                         MGI                               MGI:1926387                    

  Genetic reagent (*Mus musculus*)   Cripto^-^                                       MGI                               MGI:98658                     

  Genetic reagent (*Mus musculus*)   Lefty2^-^                                       MGI                               MGI:2443573                   

  Genetic reagent (*Mus musculus*)   Lrp2^-^                                         MGI                               MGI:95794                     

  Cell line (Human)                  HEK293T                                         ATCC                                                            

  Cell line (*Mus musculus*)         EpiSC9                                          [@bib72]                                                        [@bib37]\
                                                                                                                                                     [@bib46]

  Antibody                           anti-Smad2 (Rabbit mAB)                         Cell Signaling                    \#5339                        WB (1:1000)

  Antibody                           anti-phospho-Smad2C (Rabbit mAB)                Cell Signaling                    \#3108                        WB (1:1000)

  Antibody                           anti-phospho-Smad2L (Rabbit mAB)                Cell Signaling                    \#3104                        WB (1:1000)

  Antibody                           anti-JNK (Rabbit polyclonal)                    Cell Signaling                    \#9252                        WB (1:1000)

  Antibody                           anti-phospho-JNK (Rabbit polyclonal)            Cell Signaling                    \#9251                        WB (1:1000)

  Antibody                           anti-Gapdh (Mouse mAB)                          Cell Signaling                    \#97166                       WB (1:5000)

  Antibody                           anti-DIG AP conjugated                          Roche                             11093274910                   WM in situ (1:2000)

  Antibody                           anti-LRP2 (Goat)                                [@bib100]                                                       WB (1:1000)

  Recombinant DNA reagent            SHH-N-AP (plasmid)                              This paper                                                      

  Recombinant DNA reagent            CD164-AP (plasmid)                              This paper                                                      

  Recombinant DNA reagent            ActRIIA-AP (plasmid)                            This paper                                                      

  Recombinant DNA reagent            ALK4-AP (plasmid)                               This paper                                                      

  Recombinant DNA reagent            Cripto-AP (plasmid)                             This paper                                                      

  Recombinant DNA reagent            LRP2 sR1-Fc (plasmid)                           This paper                                                      

  Recombinant DNA reagent            LRP2 sR2-Fc (plasmid)                           This paper                                                      

  Recombinant DNA reagent            LRP2 sR3-Fc (plasmid)                           This paper                                                      

  Recombinant DNA reagent            LRP2 sR4-Fc (plasmid)                           This paper                                                      

  Recombinant DNA reagent            Cdon-Fc (plasmid)                               [@bib42]                                                        

  Peptide, recombinant protein       Human Plasma Fibronectin purified protein       MilliporeSigma                    FC010                         10 μg/ml/cm^2^

  Peptide, recombinant protein       Activin A                                       R and D Systems                   338-AC                        20 ng/ml

  Peptide, recombinant protein       FGF2                                            R and D Systems                    234-FSE                      12 ng/ml

  Peptide, recombinant protein       IgG Fc (human)                                  Jackson Laboratories              009-000-008                    

  Peptide, recombinant protein       Protein G-agarose beads                         Roche                             11243233001                   

  Peptide, recombinant protein       Anti-AP-conjugated agarose beads                Sigma                             A2080                         

  Commercial assay or kit            AP yellow liquid substrate                      Sigma                             P7998                         

  Commercial assay or kit            BM Purple                                       Roche                             11442074001\                  

  Commercial assay or kit            DIG-labeling kit                                Roche                             11277073910                   

  Commercial assay or kit            Effectene transfection reagent                  Qiagen                             301425                        

  Commercial assay or kit            RNA easy mini kit                               Qiagen                             74104                         

  Commercial assay or kit            Superscript III First strand synthesis system   Invitrogen                        18080051\                     

  Commercial assay or kit            iQ SyBR Green Supermix                          BioRad                            1708882                       

  Software, algorithm                Prism 8                                         GraphPad                          Prism 8 for MacOS ver 8.4.3   

  Sequence-based reagent             GAPDH_F                                         Invitrogen\                       PCR primers                   AACGACCCCTTCATTGAC
                                                                                     [@bib26]                                                        

  Sequence-based reagent             GAPDH_R                                         Invitrogen;\                      PCR primers                   TCCACGACATACTCAGCAC
                                                                                     [@bib26]                                                        

  Sequence-based reagent             Fgf5_F                                          Invitrogen;\                      PCR primers                   GCTGTGTCTCAGGGGATTGT
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Fgf5_R                                          Invitrogen;\                      PCR primers                   CACTCTCGGCCTGTCTTTTC
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Gbx2_F                                          Invitrogen;\                      PCR primers                   GCAACTTCGACAAAGCCGAG
                                                                                     Harvard Primer Bank 133892275c2                                 

  Sequence-based reagent             Gbx2_R                                          Invitrogen;\                      PCR primers                   CCTTGCCCTTCGGGTCATC
                                                                                     Harvard Primer Bank 133892275c2                                 

  Sequence-based reagent             Hoxa1_F                                         Invitrogen;\                      PCR primers                   CGCACAATGTTCTGATGTCC
                                                                                     [@bib62]                                                        

  Sequence-based reagent             Hoxa1_R                                         Invitrogen;\                      PCR primers                   TGCAAGCTTCATGACAGAGG
                                                                                     [@bib62]                                                        

  Sequence-based reagent             Lefty1_F                                        Invitrogen;\                      PCR primers                   AACCGCACTGCCCTTAT
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Lefty1_R                                        Invitrogen;\                      PCR primers                   CGCGAAACGAACCAACTTGT
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Lefty2_F                                        Invitrogen;\                      PCR primers                   CAGCCAGAATTTTCGAGAGGT
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Lefty2_R                                        Invitrogen;\                      PCR primers                   CAGTGCGATTGGAGCCATC
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Nanog_F                                         Invitrogen;\                      PCR primers                   GGACTTTCTGCAGCCTTACG
                                                                                     [@bib15]                                                        

  Sequence-based reagent             Nanog_R                                         Invitrogen;\                      PCR primers                   GCTTCCAAATTCACCTCCAA
                                                                                     [@bib15]                                                        

  Sequence-based reagent             Nodal_F                                         Invitrogen;\                      PCR primers                   CCTGGAGCGCATTTGGATG
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Nodal_R                                         Invitrogen;\                      PCR primers                   ACTTTCTGCTCGACTGGACA
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Pou5f1_F                                        Invitrogen;\                      PCR primers                   AGTTGGCGTGGAGACTTTGC
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Pou5f1_R                                        Invitrogen;\                      PCR primers                   CAGGGCTTTCATGTCCTGG
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Six1_F                                          Invitrogen;\                      PCR primers                   TTAAGAACCGGAGGCAAAGA
                                                                                     [@bib15]                                                        

  Sequence-based reagent             Six1_R                                          Invitrogen;\                      PCR primers                   GGGGGTGAGAACTCCTCTTC
                                                                                     [@bib15]                                                        

  Sequence-based reagent             Sox2_F                                          Invitrogen;\                      PCR primers                   GCGGAGTGGAAACTTTTGTCC
                                                                                     [@bib56]                                                        

  Sequence-based reagent             Sox2_R                                          Invitrogen;\                      PCR primers                   CGGGAAGCGTGTACTTATCCTT
                                                                                     [@bib56]                                                        

  Sequence-based reagent             T_F                                             Invitrogen;\                      PCR primers                   CTCGGATTCACATCGTGAGAG
                                                                                     [@bib56]                                                        

  Sequence-based reagent             T_R                                             Invitrogen;\                      PCR primers                   AAGGCTTTAGCAAATGGGTTGTA
                                                                                     [@bib56]                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

All animal procedures were conducted in accordance with institutional guidelines for the care and use of laboratory animals as approved by the Institutional Animal Care and Use Committee (IACUC) of the Icahn School of Medicine at Mount Sinai and according to Max-Delbruck-Center guidelines following approval by local authorities (X9007/17). B6.129P2-*Lefty2^tm1Hmd^* mice were provided by Hiroshi Hamada. *Tdgf1* mutant mice (*Cripto-LacZ* mice) were provided by Michael Shen. Both strains were transferred onto the 129S6/SvEvTac (129S6) background with the Taconic Speed Congenic Program, by backcrossing and mapping with the 1450 SNP array. Mice used for these experiments were estimated to be over 98% 129S6/SvEvTac background. These lines were crossed with *Cdon^+/tm1Rsk^* (*Cdon^+/-^*) mice on the 129S6 background ([@bib20]; [@bib33]) to generate 129S6.*Cdon^+/-^;Lefty2^+/-^* and 129S6.*Cdon^+/-^Tdgf1^+/-^* double mutant mice. Because *Cdon* and *Tdgf1* are both located on chromosome 9, *Cdon^+/-^;Tdgf1^+/-^* mice were crossed with wild type mice and offspring screened for those that carried a recombinant chromosome 9 carrying both *Cdon* and *Tdgf1* mutant alleles. Offspring of intercrosses of these mice were further crossed (see [Tables 2](#table2){ref-type="table"} and [3](#table3){ref-type="table"} for details) and pregnant females treated with EtOH or saline as a control ([@bib33]). Briefly, two- to three-month old mice were mated for one hour in the dark and plugged females were collected. The time of the plug was designated as embryonic day (E) 0.0. Pregnant female mice were injected intraperitoneally twice with 15 μl per g body weight of solution of 30% EtOH in saline (3.48 g/kg) at E7.0 and again 4 hr later. For window-of-sensitivity experiments, pregnant females were treated similarly, except the initial dose was given at E7.25 or E7.5. For studies involving *Cdon;Tdgf1* mutants, a lower dose of ethanol (25% EtOH in saline, 2.9 g/kg) was used. Saline injections were used as controls throughout.

Mice with targeted gene disruption of *Lrp2* (*Lrp2^tm1Her^*) have been described ([@bib100]). *Lrp2^+/tm1Her^* (*Lrp2^+/-^*) mice were kept on the C57BL/6N genetic background and crossed with *Cdon^+/-^* mice on the C57BL/6N genetic background. Offspring were further intercrossed, and *Lrp2^+/-^;Cdon^+/-^* mice were subjected to timed mating to collect embryos at the depicted embryonic day. Neither *Cdon^-/-^* mice nor *Lrp2^-/-^* mice on the C57BL/6N display anterior truncation phenotypes.

Whole mount in situ hybridization {#s4-2}
---------------------------------

Whole mount RNA in situ hybridization was performed according to standard protocols ([@bib33]). Briefly, embryos were dissected out and fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), dehydrated through a graded methanol series, and stored at −20°C. Rehydrated embryos were treated with 10 μg/ml proteinase K (Qiagen) in PBS, 0.1% Tween-20 (PBST) according to stage. Embryos were rinsed with PBST, post-fixed and hybridized with digoxygenin (DIG)-labeled probe in hybridization mix (50% formamide, 1.3x SSC pH 5.0, 5 mM EDTA, 50 μg/ml yeast tRNA, 100 μg/ml heparin, 0.2% Tween-20, and 0.5% CHAPS) overnight at 65°C. They were washed, blocked with 2% Roche blocking reagent, 20% heat-inactivated lamb serum in Tris-buffered saline with 0.1% Tween-20 (TBST) and incubated with alkaline phosphate-conjugated anti-DIG antibody (1:2000, Roche) in blocking buffer overnight at 4°C. After washing with TBST and NTMT (100 mM NaCl, 100 mM Tris pH9.5, 50 mM MgCl~2~, and 0.1% Tween-20), embryos were stained with BM Purple AP substrate (Roche) in the dark. Stained embryos were cleared in 80% glycerol and photographed with a Jenoptik ProgRes C3 camera attached to Nikon SMZ 1500 stereomicroscope. Captured images were assembled by Helicon Focus software (Helicon Soft).

Mouse epiblast stem cell culture and western blot and qRT-PCR analysis {#s4-3}
----------------------------------------------------------------------

Mouse epiblast stem cells (EpiSC9 cells) were obtained from Jianlong Wang, authenticated by robust expression of pluripotency markers, and confirmed to be negative for mycoplasma infection. EpiSC9 cells were cultured as described ([@bib37]). Briefly, cells were cultured on 0.1% fibronectin-coated plates (MilliporeSigma, 10 μg/ml/cm^2^) in N2B27 media supplemented with 20 ng/ml Activin A (R and D Systems) and 12 ng/ml Fgf2 (R and D Systems). Media were changed daily. EpiScs were treated with EtOH for six hours in fresh EpiSC media with supplements. For protein analysis, cells were harvested with RIPA buffer plus protease inhibitor (Sigma) and phosphatase inhibitor (Sigma). Western blotting was as described ([@bib8]). Images were scanned and quantified using ImageJ software. Statistical significance was calculated using Student's t-test and a cutoff of p\<0.05. Primary antibodies used for western blot: SMAD2 (Cell Signaling \#5339), p-SMAD2C (Cell Signaling \#3108), p-SMAD2L (Cell Signaling \#3104), JNK (Cell Signaling \#9252), p-JNK (Cell Signaling \#9251), and GAPDH (Cell Signaling \#97166). For mRNA analysis, total RNA was extracted from EpiSCs using the RNAeasy kit (Quiagen). Reverse transcription and cDNA production were performed with Superscript III first strand synthesis system (Invitrogen). qPCR was performed using iQ SyBR green supermix (BioRad) on an iCycler iQ5 (BioRad). Gene expression levels were normalized to *Gapdh*.

Protein-protein interactions {#s4-4}
----------------------------

Expression vectors encoding soluble, tagged forms of CDON, SHH-N, CD164, ActRIIA, ActRIIB, ALK4, TDGF1, and LRP2, and LRP2 mini-receptors that encoded the LRP2 transmembrane and intracellular domains, were constructed by standard methods; details are available on request. HEK293T cells were obtained from ATCC, confirmed to be negative for mycoplasma infection, and cultured in DMEM with 10% FBS and 1x Penicillin/Streptomycin. HEK293T cells in 10 cm dishes were transfected with a total of either 2 or 3 μg of plasmid vectors using Effectene reagent (Qiagen). Media were changed to 2% FBS two days after transfection. Conditioned media were harvested five days afterwards. Soluble fusion proteins in conditioned media were quantified by dot blotting with human IgG Fc protein (Jackson ImmunoResearch Laboratories) as a standard, and by alkaline phosphatase (AP) enzyme activity using AP yellow liquid substrate (Sigma). For analysis of CDON-Fc interactions with soluble AP-tagged proteins, the factors were coexpressed in HEK293T cells. For Fc pull down and AP activity assays with CDON-Fc, soluble fusion proteins were incubated with protein G agarose beads (Roche) for 2 hr at 4°C. For analysis of soluble LRP2-Fc mini-receptors interactions with soluble AP-tagged proteins, LRP2 sR1-sR4 and the AP-tagged counterparts were generated separately in individual transfections and CM mixed together. Pull down complexes were washed five times with ice-cold HNTG buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol). Endogenous AP was inactivated by heat inactivation. AP activity in pull-down complexes was measured using AP yellow liquid substrate (Sigma). For AP pull down followed by western blot analysis, soluble fusion proteins were incubated with anti-AP conjugated agarose beads (Sigma) overnight at 4°C. Pull-down complexes were washed five times with HNTG buffer, eluted from the beads by boiling, and separated by SDS-PAGE. Antibodies used for western blot were HRP conjugated with goat anti-human Fc.

To test SHH-N interaction with membrane-bound LRP2 mini-receptors, NIH3T3 cells were transfected with the four individual LRP2 mini-receptors encoding transmembrane and intracellular domains and incubated with 20 μg/ml GST-SHH-N in the medium for two hours. Cell lysates were immunoprecipitated with polyclonal LRP2 antibody directed against full-length LRP2, and subjected to western blot analysis with anti-LRP2 and anti-GST antibodies.
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We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.

Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

Holoprosencephaly (HPE) is a common birth defect in human with genetic and environmental causes. Prominent among the genetic causes are component of the Nodal and Hedgehog signaling pathways. In previous studies the group of R. Krauss has shown that mutations in the *Cdon* gene (which is known to act as a HH binding protein) and in utero exposure to ethanol produced HPE with a penetrance not observed when the two factors are considered individually. The present study offers an important mechanistic insight into mechanism underlying this synergy. It shows that Nodal is the target upon which prenatal alcohol exposure converges with *Cdon* mutations in causing the brain and face malformations of holoprosencephaly. The manuscript thus expands on the present understanding of alcohol teratogenesis and *Cdon* role in embryogenesis demonstrating how these factors interact.

Essential revisions:

There is general consensus that this a very valuable and well performed study that adds important information on the interaction between environmental and genetic factors in the development of HPE.

There are however a number of issues that need your attention:

1\) The data rule out the participation of HH signaling in the presented phenotype are not strong and mostly based on previous studies in which differences in mouse strain, breeding etc. may make the comparison with the present study questionable. Thus, at minimum, you reconsider the interpretation of the data and tone down the conclusions.

2\) There is also too much speculation related to the role of CDON variants in humans. This needs to be addressed.

3\) Please also address the state of p-SMAD2C in ethanol treated embryos and in *Cdon*, *Lrp2* double mutant embryos.

4\) To sustain the conclusions related to the Nodal signaling activity please also analyze additional target genes such as *Gsc*.

Reviewer \#1:

General assessment: The manuscript by Hong et al. provides evidence pointing toward Nodal as a target upon which prenatal alcohol exposure converges with *Cdon* mutations in causing the brain and face malformations of holoprosencephaly. Dissecting the interaction of specific genetic and chemical influences is an important but challenging focus of birth defects research. The manuscript offers an exceptional degree of mechanistic insight that challenges the existing understanding of alcohol teratogenesis, expands the role of *Cdon* in embryogenesis, and points to how these factors interact. While some interpretations rely on interpolation of historical data and probably should be dialled back, on balance the study appears high quality and the findings novel, making the work as a whole a significant advance in the field.

1\) The data supporting ethanol acting (at least in part) upstream of HH on Nodal is strong and compelling. However, the argument against alcohol acting (at least in part) on HH pathway is less convincing, not supported by strong direct evidence, and relies on comparison of new and historical data. For example, the authors state that the window of sensitivity to EtOH-induced HPE in 129S6 *Cdon*^-/-^ mice is closed by E7.5, prior to *Shh* expression in the midline which begins at E7.5-7.75 but contemporaneous evidence is lacking. The strain of mice, breeding strategy, and staging nomenclature may have differed between the present study and that cited for *Shh* expression timing (Echalard). The authors show no effect of ethanol exposure at E7.5. Dosing at E7.25 however does have an effect but this follows a dose at E7.25 and another 4 hours later, making it likely that ethanol exposure persists through E7.5. Dialling back the interpretation of these data and focusing more on those supporting Nodal as a newly identified target of ethanol and point of synergism between ethanol and *Cdon* would mitigate this concern. This need not detract from the impact of the novel findings presented. As the authors note, alcohol may perturb cell membranes and receptor trafficking/function, so mechanisms/targets are unlikely to be mutually exclusive.

Reviewer \#2:

This is a very well written manuscript and important for HPE research. I believe this is a \"must publish\" manuscript. This study addresses the \"Holy Grail\" of genetics of modifiers, incomplete penetrance and variable expressivity. This study is also a beautiful continuation of this group\'s narrative on CDON and ETOH.

Until this study, CDON was thought to act mainly through HH signaling, and this is a first in showing the CDON-Nodal signaling relationship. The mouse knockout and epiblast stem cell experiments are fantastic and convincing. There few studies with this high-quality figures.

My most significant comment is that the authors speculate too much about the role of CDON variants in humans. If you dig deep into the published literature, there is not a strong association with CDON and HPE in humans (driver or modifier). There is one fact that cannot be ignored: in healthy humans, loss of function variants in CDON is common, which is very different from the known associated HPE genes such as SHH, ZIC2, SIX3, STAG2, SMC1A etc. Therefore, it will take a large epidemiologic study to connect CDON and ETOH in humans. The data is just not there in humans to connect alcohol and CDON variation (yet).

1\) Introduction: \"animal models are required...\" is debatable. The mouse model behaves very differently than humans in regard to the genetics of HPE; for example, only a heterozygous variant in SHH results in HPE in humans where heterozygous mice with SHH variants are normal. Animal models are a surrogate for human studies that are underpowered; especially, in conditions such as HPE which is rare. There have been attempts in humans to answer the question of environmental effects on HPE, see Addissie et al., 2020, again study power is an issue.

2\) Introduction: Addissie et al., 2020 should be referenced here. Also, recommend reviewing Addissie et al.

3\) I do not believe there is sufficient evidence to associate CDON with HPE in humans. In the largest study mentioning CDON\'s association with HPE, some of the variants were (1) transmitted from a parent; and (2) a missense variant without functional evidence of pathogenicity. These CDON variants are variants of unknown significance. Commercial labs often misinterpret these gene associations with HPE and it is very important to be precise here, i.e. see https://www.invitae.com/en/physician/tests/04424/\#info-panel-assay_information. See my next comment. I believe the authors have misinterpreted the findings in Roessler et al., 2018a.

4\) It should be noted that CDON loss of function variants are commonly found in healthy human individuals (observed / expected ration of 0.58; https://gnomad.broadinstitute.org/gene/ENSG00000064309?dataset=gnomad_r2_1), showing that CDON loss of function variants are not constrained by evolution. This is very important and it supports the authors\' findings that most alcohol is needed with a CDON variant to reach the HPE threshold in mice and most likely (though not proven) in humans.

Reviewer \#3:

Holoprosencephaly (HPE) is a common birth defect in human. Many genes such as those in Nodal and Hedgehog signaling are implicated in HPE, but environmental factors also contribute. The authors previously showed that a mutation in *Cdon* gene or in utero exposure to ethanol individually had little effect, but the combination of both produced HPE with high penetrance. However, it was unknown how *Cdon* mutation and ethanol synergize for HPE.

In this paper, the authors conclude that *Cdon* and ethanol converge to Nodal signaling. Involvement of *Cdon* in Nodal signaling was supported by genetic and physical interaction between *Cdon* and Cripto (a coreceptor of Nodal). Effects of ethanol on Nodal signaling was examined with mouse epiblast stem cells, and ethanol was shown to inhibit C-terminal phosphorylation of SMAD2, a readout of Nodal activity. Collectively, it was concluded that *Cdon* mutation and in utero ethanol synergistically inhibit Nodal signaling, producing HPE.

In all, this paper provides a nice example showing how interaction between a gene and an environmental factor affects a particular developmental process. Since many of genetic disorders in human likely involve multiple factors, genetic and environmental factors, this paper has important messages. To be published in *eLife*, however, the following points need to be addressed.

1\) Authors provide a nice set of data showing that ethanol inhibits SMAD2 C-terminal phosphorylation in mouse epiblast stem cells (Figure 2A, 2B). This is excellent. However, it is more important to see the effects of ethanol with mouse embryos. This can be done by staining of mouse embryos such as those shown in Figure 1 with the anti-phosphorylated SMAD2C (the antibody is commercially available and has been used by others). Similarly, I would like to suggest examining p-SMAD2C in *Cdon*, *Lrp2* double mutant embryos too (Figure 3A; whole mount staining may be easier at an earlier stage than E11.5). This would strengthen the conclusion that *Cdon* and ethanol synergistically affect Nodal signaling in mouse embryos.

2\) *Lefty2* expression is regulated by Nodal, but *Lefty2* protein inhibits Nodal activity, which makes a complex network. It is preferable to examine additional Nodal target genes such as Gsc in Figure 1. Also, is Nodal expression maintained in *Cdon*^-/-^, EtOH embryos (Figure 1)?

10.7554/eLife.60351.sa2

Author response

> Essential revisions:
>
> There is general consensus that this a very valuable and well performed study that adds important information on the interaction between environmental and genetic factors in the development of HPE.
>
> There are however a number of issues that need your attention:
>
> 1\) The data rule out the participation of HH signaling in the presented phenotype are not strong and mostly based on previous studies in which differences in mouse strain, breeding etc. may make the comparison with the present study questionable. Thus, at minimum, you reconsider the interpretation of the data and tone down the conclusions.

We agree with the reviewer's point and have modified the text in the Abstract, Results section, and Discussion section to temper our conclusions. Additionally, we state in the Discussion section, "Our findings do not exclude that EtOH may also target HH signaling in *Cdon*^-/-^ mice, but they are consistent with Nodal signaling being a major target of EtOH in HPE."

> 2\) There is also too much speculation related to the role of CDON variants in humans. This needs to be addressed.

We agree that the role of CDON variants in human HPE is not fully clear. We have made this overt in the Introduction.

> 3\) Please also address the state of p-SMAD2C in ethanol treated embryos and in Cdon, Lrp2 double mutant embryos.

As described above, we will perform these experiments as soon as possible and report them as suggested by the editors. We have added text to the Discussion section to state explicitly that these experiments are required.

> 4\) To sustain the conclusions related to the Nodal signaling activity please also analyze additional target genes such as Gsc.

We thank the reviewer for this comment. We have in fact analyzed expression of *Gsc* and *FoxA2*, two additional Nodal target genes important for PCP induction. Expression of *Gsc* and *FoxA2* are specifically reduced in EtOH-treated *Cdon* mutant embryos, similar to expression of *Lefty2*. These results were published in Hong and Krauss (2012), cited in the references. This was stated in the original version of the paper, but we have made this clearer in the revised manuscript (subsection *"Cdon* interacts genetically with Nodal pathway components" and Discussion section).

> Reviewer \#1:
>
> \[...\]
>
> 1\) The data supporting ethanol acting (at least in part) upstream of HH on Nodal is strong and compelling. However, the argument against alcohol acting (at least in part) on HH pathway is less convincing, not supported by strong direct evidence, and relies on comparison of new and historical data. For example, the authors state that the window of sensitivity to EtOH-induced HPE in 129S6 Cdon^-/-^ mice is closed by E7.5, prior to Shh expression in the midline which begins at E7.5-7.75 but contemporaneous evidence is lacking. The strain of mice, breeding strategy, and staging nomenclature may have differed between the present study and that cited for Shh expression timing (Echalard). The authors show no effect of ethanol exposure at E7.5. Dosing at E7.25 however does have an effect but this follows a dose at E7.25 and another 4 hours later, making it likely that ethanol exposure persists through E7.5. Dialling back the interpretation of these data and focusing more on those supporting Nodal as a newly identified target of ethanol and point of synergism between ethanol and Cdon would mitigate this concern. This need not detract from the impact of the novel findings presented. As the authors note, alcohol may perturb cell membranes and receptor trafficking/function, so mechanisms/targets are unlikely to be mutually exclusive.

We have made the requested changes to the text (please see the response to Essential revisions, point 1, above).

> Reviewer \#2:
>
> \[...\]
>
> My most significant comment is that the authors speculate too much about the role of CDON variants in humans. If you dig deep into the published literature, there is not a strong association with CDON and HPE in humans (driver or modifier). There is one fact that cannot be ignored: in healthy humans, loss of function variants in CDON is common, which is very different from the known associated HPE genes such as SHH, ZIC2, SIX3, STAG2, SMC1A etc. Therefore, it will take a large epidemiologic study to connect CDON and ETOH in humans. The data is just not there in humans to connect alcohol and CDON variation (yet).

We have made the requested changes to the text (please see the response to Essential revisions, point 2, above).

> 1\) Introduction: \"animal models are required...\" is debatable. The mouse model behaves very differently than humans in regard to the genetics of HPE; for example, only a heterozygous variant in SHH results in HPE in humans where heterozygous mice with SHH variants are normal. Animal models are a surrogate for human studies that are underpowered; especially, in conditions such as HPE which is rare. There have been attempts in humans to answer the question of environmental effects on HPE, see Addissie et al., 2020, again study power is an issue.

We thank the reviewer for this comment. We have substituted the word "valuable" for the word "required". We point out that this statement is consistent with a statement from HPE epidemiologists: "More data from in vitro and animal models might be necessary to identify the most biologically plausible risk factors." (Miller at al. 2010, in the references).

We agree the Addissie et al., paper is highly relevant to the discussion and have cited it twice in the text (Results section).

> 2\) Introduction: Addissie et al., 2020 should be referenced here. Also, recommend reviewing Addissie et al.

We agree the Addissie et al. paper is highly relevant to the discussion and have cited it twice in the text (Results section).

> 3\) I do not believe there is sufficient evidence to associate CDON with HPE in humans. In the largest study mentioning CDON\'s association with HPE, some of the variants were (1) transmitted from a parent; and (2) a missense variant without functional evidence of pathogenicity. These CDON variants are variants of unknown significance. Commercial labs often misinterpret these gene associations with HPE and it is very important to be precise here, i.e. see https://www.invitae.com/en/physician/tests/04424/\#info-panel-assay_information. See my next comment. I believe the author have misinterpreted the findings in Roessler, 2018a.
>
> 4\) It should be noted that CDON loss of function variants are commonly found in healthy human individuals (observed / expected ration of 0.58; https://gnomad.broadinstitute.org/gene/ENSG00000064309?dataset=gnomad_r2_1), showing that CDON loss of function variants are not constrained by evolution. This is very important and it supports the authors\' findings that most alcohol is needed with a CDON variant to reach the HPE threshold in mice and most likely (though not proven) in humans.

We have made the requested changes to the text (please see the response to Essential revisions, point 2, above).

> Reviewer \#3:
>
> \[...\]
>
> 1\) Authors provide a nice set of data showing that ethanol inhibits SMAD2 C-terminal phosphorylation in mouse epiblast stem cells (Figure 2A, 2B). This is excellent. However, it is more important to see the effects of ethanol with mouse embryos. This can be done by staining of mouse embryos such as those shown in Figure 1 with the anti-phosphorylated SMAD2C (the antibody is commercially available and has been used by others). Similarly, I would like to suggest to examine p-SMAD2C in Cdon, Lrp2 double mutants embryos too (Figure 3A; whole mount staining may be easier at an earlier stage than E11.5). This would strengthen the conclusion that Cdon and ethanol synergistically affect Nodal signaling in mouse embryos.

In lieu of not performing these experiments immediately, we have made requested changes to the text (please see the response to Essential revisions, point 3, above). We will perform these experiments and report back as soon as possible.

> 2\) Lefty2 expression is regulated by Nodal, but Lefty2 protein inhibits Nodal activity, which makes a complex network. It is preferable to examine additional Nodal target genes such as Gsc in Figure 1. Also, is Nodal expression maintained in Cdon^-/-^, EtOH embryos (Figure 1)?

We thank the reviewer for this comment. We have indeed assessed expression of *Gsc* and *FoxA2*. This was mentioned in the first version of the manuscript, but we have now made this clearer (please see the response to Essential revisions, point 4, above). We will assess Nodal expression at the same time we examine p-SMAD2C production in embryos and report back.
